4Dcell Achieves 95% Organoid Reproducibility Breakthrough With Patented Anchoring Technology

4Dcell announced that its SmartSphero plates have achieved over 95% reproducibility in organoid size and shape, while reducing organoid loss during medium exchanges to below 12%, a significant improvement over the 86% loss seen in traditional unanchored systems. This breakthrough addresses a persistent challenge in pharmaceutical drug screening and safety testing, where inconsistent organoid cultures have often hindered data reliability.

The company's patented Anchoring Point Technology (APT®) allows researchers to culture up to 5,000 uniform organoids per plate, all aligned on a single focal plane for simplified imaging. Validation studies using vascularized breast cancer models showed maintained cell viability above 85% after seven days, with successful co-cultures including macrophages and endothelial cells.

"The pharmaceutical industry has been struggling with organoid variability and loss during routine lab procedures," said Yajush Gupta, Assistant Growth and Marketing Analyst at 4Dcell. "Our technology finally gives researchers the reproducibility they need for statistically meaningful drug screening studies, while dramatically reducing the time spent scanning across multiple focal planes during imaging."

SmartSphero has been validated across a range of tissue types, including breast, lung, and adipose models, and is compatible with both immortalized cell lines and primary tissue dissociations. The plates integrate easily with standard automated liquid handling systems and conventional microscopy platforms.

Company Website: www.4dcell.com
SmartSphero Technology: https://www.4dcell.com/smartsphero

Address
14 rue de la Beaune
93100 Montreuil (Paris area)
France

About 4Dcell
4Dcell develops advanced organoid culture technologies for pharmaceutical research and drug discovery. Based in Paris, the company's patented SmartSphero technology addresses critical reproducibility challenges in organoid-based drug screening and safety assessment. The company's solutions enable high-throughput studies for DMPK (Drug Metabolism and Pharmacokinetics), safety, and efficacy assessment applications across multiple tissue types.

Technical Background
The SmartSphero plates utilize patented Anchoring Point Technology (APT®) featuring cell-repellent hydrogel microwells with contact points that anchor spheroids in predictable locations. The anti-adhesive properties facilitate rapid self-assembly of cell aggregates into compact spheroids while preventing loss during routine laboratory manipulations such as medium exchanges and drug additions.
The technology is compatible with standard laboratory equipment including brightfield, fluorescence, and confocal microscopy systems, as well as automated liquid handling platforms. The #1.5 glass-bottom design supports high-resolution imaging across all conventional microscopy systems.

Validation Data
Independent studies have demonstrated the technology's effectiveness across various applications including vascularized immunocompetent cancer models, with successful integration of multiple cell types including tumor cells, macrophages, endothelial cells, and fibroblasts. The system supports both immortalized cell lines and primary tissue dissociations.

This release was published on openPR.